

1965. Sulphasalazine

RCT/Prednisone/UC/ Maintain

Controlled Trial Of Sulphasalazine In Maintenance Therapy For Ulcerative Colitis

Randomized double-blind controlled trial. Patients with UC (left sided or pancolitis) asymptomatic and in endoscopic remission who had a UC flare the year before were randomized to sulphasalazine 2gr/day vs placebo.

Primary endpoints: Remission within a year

Results: N=67

- Remission within a year: 70.6% sulphasalazine vs 21.2% placebo, $p < 0.001$
- Of the patients relapsing, 75% of them occurred within the first 3 months.

Conclusion:

This is the first demonstration in a formal trial that any treatment reduces the relapse-rate in ulcerative colitis. 70.6% of patients taking 2 g. of sulphasalazine daily remained free of symptoms for a year.




Fig. 2—Results of trial.




Fig. 3—Cumulative relapse-rate in the two groups.

